Quick Answer
Regen BioPharma Inc reported Total Revenue of $236.6 thousand for fiscal year 2025.
Regen BioPharma Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $236.6K +0.0% |
$236.6K +86.9% |
$126.6K +0.8% |
$125.5K +105.1% |
$61.2K -44.4% |
$110.0K +0.0% |
| Revenue (ASC 606) | $236.6K +0.0% |
$236.6K +0.0% |
$236.6K | — | — | — |
| Net Income | -$1.27M -90.7% |
-$668.3K -157.8% |
$1.16M -52.7% |
$2.44M +136.1% |
-$6.77M -298.1% |
$3.41M +230.2% |
| Diluted EPS | -$0.05 +68.8% |
-$0.16 -155.2% |
$0.29 -59.2% |
$0.71 | — | — |
| Total Assets | $274.6K +70.5% |
$161.1K -54.4% |
$353.6K -36.7% |
$559.0K -53.9% |
$1.21M +883.9% |
$123.2K +24.3% |
| Cash and Equivalents | $69.6K +9614.4% |
$716.00 -99.4% |
$121.0K +136.4% |
$51.2K -93.0% |
$727.2K | $0.00 -100.0% |
| Stockholders Equity | -$6.28M -20.4% |
-$5.22M -5.8% |
-$4.93M +93.6% |
-$76.75M -1413.6% |
-$5.07M +30.9% |
-$7.33M |
| R&D Expense | $11.7K -92.4% |
$153.7K -27.6% |
$212.3K +34.2% |
$158.1K +330.8% |
$36.7K +176.3% |
$13.3K -70.9% |
| Operating Income | -$338.5K +18.9% |
-$417.2K +39.3% |
-$687.0K -102.3% |
-$339.6K -69.2% |
-$200.8K +4.1% |
-$209.3K +72.3% |
| Shares Outstanding | 39.37M +648.8% |
5.26M +50.0% |
3.51M +4.5% |
3.35M -99.9% |
4.35B +171.1% |
1.61B +790.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $59.1K | +0.0% | +0.0% |
| Revenue (ASC 606) | December 31, 2025 | $59.1K | +0.0% | +0.0% |
| Net Income | December 31, 2025 | -$967.9K | -87.8% | -478.5% |
| Diluted EPS | December 31, 2025 | -$0.01 | +92.3% | +0.0% |
| Total Assets | December 31, 2025 | $237.1K | +23.9% | -13.7% |
| Cash and Equivalents | December 31, 2025 | $4.6K | +3291.1% | -93.4% |
| Stockholders Equity | December 31, 2025 | -$6.57M | -15.7% | -4.6% |
| R&D Expense | December 31, 2025 | $210.0K | — | — |
| Operating Income | December 31, 2025 | -$551.6K | -798.7% | -1253.5% |
| Shares Outstanding | December 31, 2025 | 108.05M | +401.3% | +174.4% |
- Regen BioPharma Inc reported Total Revenue of $236.6 thousand for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +0.0% in Total Revenue compared to the prior fiscal year.
- Regen BioPharma Inc reported Revenue (ASC 606) of $236.6 thousand for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +0.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Regen BioPharma Inc reported Net Income of -$1.27 million for fiscal year 2025.
- Regen BioPharma Inc showed a decrease of -90.7% in Net Income compared to the prior fiscal year.
- Regen BioPharma Inc reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +68.8% in Diluted EPS compared to the prior fiscal year.
- Regen BioPharma Inc reported Total Assets of $274.6 thousand for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +70.5% in Total Assets compared to the prior fiscal year.
- Regen BioPharma Inc reported Cash and Equivalents of $69.6 thousand for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +9614.4% in Cash and Equivalents compared to the prior fiscal year.
- Regen BioPharma Inc reported Stockholders Equity of -$6.28 million for fiscal year 2025.
- Regen BioPharma Inc showed a decrease of -20.4% in Stockholders Equity compared to the prior fiscal year.
- Regen BioPharma Inc reported R&D Expense of $11.7 thousand for fiscal year 2025.
- Regen BioPharma Inc showed a decrease of -92.4% in R&D Expense compared to the prior fiscal year.
- Regen BioPharma Inc reported Operating Income of -$338.5 thousand for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +18.9% in Operating Income compared to the prior fiscal year.
- Regen BioPharma Inc reported Shares Outstanding of 39.37 million shares for fiscal year 2025.
- Regen BioPharma Inc showed an increase of +648.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: